U
Alumis Inc.
Recommendation
--
Prev Close
--
Volume
--
Avg Vol (90D)
--
Market Cap
$371.60M
Dividend & Yield
--
52-Week Range
-- - --
P/E (TTM)
--
EPS (TTM)
-$47.61
My Lists My Alerts
Rating
Reward
U
Unrated
Risk
U
Unrated
Rating Factors
Growth Index
Unrated
Efficiency Index
Unrated
Solvency Index
Unrated
Total Return Index
Unrated
Volatility Index
Unrated
Dividend Index
Unrated
Headlines
There are no news to display.
Income Statement
Total Revenue (TTM)
--
EBITDA (TTM)
-$297.60M
EBIT (TTM)
-$300.75M
Net Income (TTM)
-$294.23M
Balance Sheet
Total Assets (Q)
$340.99M
Total Debt (Q)
$30.72M
Total Liabilities (Q)
$80.89M
Book Value Per Share (Q)
$4.78
Cash Flow
Cash from Operations (TTM)
-$255.08M
Cash from Investing (TTM)
-$113.79M
Cash from Financing (TTM)
$492.37M
Net Change in Cash (TTM)
$123.50M
Filings
Filing Date
Wednesday, March 19, 2025
Period Date
Tuesday, December 31, 2024
Next Filing
Week of Jun 2 and 6 (est)
Price History
Loading...
Beta
--
7-Day Total Return
--
30-Day Total Return
--
60-Day Total Return
--
90-Day Total Return
--
Year to Date Total Return
--
1-Year Total Return
--
2-Year Total Return
--
3-Year Total Return
--
5-Year Total Return
--
52-week Low
-- - --
52-week High
-- - --
Valuation
Market Cap
$371.60M - Small Cap
Enterprise Value
$114.06M
Price/Sales (TTM)
--
Price/Book (Q)
--
Dividends and Shares
Shares Outstanding
54.42M
Dividend Per Share (Most Recent)
--
Dividend Per Share (TTM)
--
Corporate Info
Website
www.alumis.com
Phone Number
650 231 6625
Address
280 East Grand Avenue
South San Francisco, CA 94080
Country
United States
Year Founded
2021
Business Description
Sector
Health Care
Industry
Pharmaceuticals, Biotechnology and Life Sciences
Alumis Inc., a clinical stage biopharmaceutical company, focuses on identifying, acquiring, and accelerating the development and commercialization of medicines for autoimmune disorders. The... more
Weiss Ratings